Development of a low-seroprevalence, avß6 integrin-selective virotherapy based on human adenovirus type 10. (2022)
Attributed to:
MICA: Targeting the Wnt Receptor Frizzled-7 for the Treatment of Gastric Cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.omto.2022.03.007
PubMed Identifier: 35399606
Publication URI: http://europepmc.org/abstract/MED/35399606
Type: Journal Article/Review
Volume: 25
Parent Publication: Molecular therapy oncolytics
ISSN: 2372-7705